HARP - Harpoon stock soars 26% on Wedbush upgrade ahead of HPN328 data in lung cancer at ASCO

Harpoon Therapeutics (NASDAQ:HARP) stock rose ~26% on May 16 after Wedbush upgraded the company's shares to Outperform from Neutral with a price target of $7, up from $5, on model tweaks related to the HPN328 program. Wedbush analyst is awaiting updated data from a phase 1/2 study of HPN328 at the American Society of Clinical Oncology (ASCO) annual meeting which the analyst expects will support a planned combination study with atezolizumab in small cell lung cancer (SCLC). The analyst also expects a positive update, seeing that promising data at the higher doses studied in the ongoing dose-escalation part. Harpoon had noted in its May 12 earnings release that it plans to present interim results from the ongoing phase 1 part of the study at ASCO on June 6. HPN328 works by targeting a type of protein called DLL3, and is in a phase 1/2 trial for SCLC and and neuroendocrine cancers. HPN328 has

For further details see:

Harpoon stock soars 26% on Wedbush upgrade ahead of HPN328 data in lung cancer at ASCO